U.S. Markets closed

Generex Biotechnology Corporation (GNBT)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.810.00 (0.00%)
At close: 3:29PM EDT
People also watch
HEBNVAXCVMBCRXGNVC

Generex Biotechnology Corporation

4145 North Service Road
Suite 200
Burlington, ON L7L 6A3
Canada
416-364-2551
http://www.generex.com

SectorHealthcare
IndustryDrug Delivery
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Mark A. Fletcher Esq.Exec. VP, Gen. Counsel and Sec.71.46kN/A52
Dr. Eric von Hofe Ph.D.VP and Pres of Antigen Express IncN/AN/A62
Mr. Joseph MoscatoChief Exec. Officer, Pres and DirectorN/AN/A53
Mr. Mark CorraoChief Financial Officer and TreasurerN/AN/A60
Mr. Andrew Greene Esq.Chief Operating Officer and DirectorN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Generex Biotechnology Corporation does not have significant business operations. Previously, it was engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It focused on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. The company developed Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator for the treatment of Type 1 and Type 2 diabetes. It also engaged in the development of immunomedicine technology and products for the treatment of breast, prostate, and ovarian cancers; melanoma; influenza; HIV; and autoimmune diseases, such as diabetes and multiple sclerosis. Further, the company offered immunomedicine technology and products, which included immunotherapeutic vaccine AE37 for patients with HER-2/neu positive breast cancer and for patients with prostate cancer; and synthetic peptide vaccines for H5N1 avian influenza and H1N1 swine flu. Generex Biotechnology Corporation was founded in 1983 and is based in Burlington, Canada.

Corporate Governance

Generex Biotechnology Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.